Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Drug

AbbVie Completes Acquisition of Cerevel Therapeutics in $8.7 Billion Deal

Fineline Cube Aug 2, 2024

US pharmaceutical giant AbbVie Inc. (NYSE: ABBV) has announced the successful completion of its acquisition...

Company Medical Device

Sino Medical Sciences’ HT Supreme Drug-Eluting Stent System Gains Market Approval in Mexico

Fineline Cube Aug 2, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), a prominent player in the medical device industry...

Company Drug

Lee’s Pharmaceutical Commences Phase I Clinical Trial for AI-Discovered HCC Drug AU409

Fineline Cube Aug 2, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading biopharmaceutical company based in China, has announced...

Company Medical Device

Roche’s Alzheimer’s Disease Diagnostic Kits Gain Approval in Hainan, Set for Use in Shanghai Ruijin Hospital

Fineline Cube Aug 2, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has received approval from the Hainan Medical...

Company Deals

Mabwell Bioscience Secures Rights to Risen Pharmaceutical’s OA Treatment in Greater China

Fineline Cube Aug 2, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a leading biopharmaceutical company in China, has entered...

Company Drug

Suzhou Zelgen’s Jacktinib Tablets Achieve Positive Results in Phase II IPF Clinical Trial

Fineline Cube Aug 2, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Deals

ImmuneOnco Biopharmaceuticals Strikes Licensing Deal with Instil Bio for Global Rights to Dual-Targeted Antibodies

Fineline Cube Aug 2, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has entered into a definitive licensing agreement with...

Company Drug

Sino Biopharmaceutical’s Benmelstobart Files for New Indication in China for Advanced RCC Treatment

Fineline Cube Aug 2, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced that...

Company Medical Device

AbbVie’s Allergan Aesthetics Wins NMPA Approval for Juvéderm Dermal Filler in China

Fineline Cube Aug 2, 2024

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has secured marketing approval from China’s National...

Company Drug

Innovent Biologics’ Mazdutide NDA for Type 2 Diabetes Accepted for Review in China

Fineline Cube Aug 2, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...

Company Drug

GSK’s Jemperli Receives EC Approval for Endometrial Cancer Treatment in Combination Therapy

Fineline Cube Aug 2, 2024

GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced that the European Commission...

Company Deals

Fapon Biotech Expands Global Footprint with New IVD Manufacturing Facility in Indonesia

Fineline Cube Aug 2, 2024

China-based in vitro diagnostic (IVD) company Fapon Biotech has announced a strategic investment with the...

Company Deals

Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus

Fineline Cube Aug 2, 2024

Japan’s pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of...

Company Deals

Otsuka Pharmaceutical to Acquire US Biotech Jnana Therapeutics in $1.1 Billion Deal

Fineline Cube Aug 2, 2024

Otsuka Pharmaceutical Co., Ltd, a leading Japanese pharmaceutical company, has announced the signing of a...

Policy / Regulatory

US Lawmakers Probe Clinical Trials at Hospitals Linked to Chinese Military, Potential Impact on Pharma Industry

Fineline Cube Aug 1, 2024

Reports from BioCentury and Endpoints News, based on anonymous insider sources, suggest that US lawmakers...

Policy / Regulatory

China’s Health Authorities Set Standards for Key Central Township Health Centers

Fineline Cube Aug 1, 2024

The National Health Commission (NHC), National Disease Control and Prevention Administration, and National Administration of...

Policy / Regulatory

China’s State Council Unveils Five-Year Plan to Enhance Urbanization and Address “Three Rural Issues”

Fineline Cube Aug 1, 2024

The State Council of China has released a “Five Year Action Plan for Deepening the...

Policy / Regulatory

Shanghai Aims to Become Capital Market Hub for High-Quality Science and Innovation Companies

Fineline Cube Aug 1, 2024

The Shanghai municipal government has unveiled a comprehensive set of measures designed to enhance the...

Company Deals Legal / IP

Sirnaomics Ltd Forms JV with Gore Range Capital to Pioneer Medical Aesthetics Innovations

Fineline Cube Aug 1, 2024

Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company specializing in RNAi therapeutics, has announced the formation...

Company Medical Device

MicroPort Scientific’s Bioabsorbable Stent System Gains NMPA Nod for Ischemic Heart Disease Treatment

Fineline Cube Aug 1, 2024

Shanghai-based medical device conglomerate MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...

Posts pagination

1 … 372 373 374 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.